Post by Thermo Fisher Scientific

At BIO 2026, Thermo Fisher’s Daniella Cramp joined TrilliumBiO’s Kellen Voss, PhD for a discussion moderated by Kaustabh Basu Ph.D. on how advances in science, AI, diagnostics, biologics and manufacturing are reshaping the path from discovery to patient impact. The conversation focused on a critical opportunity for the industry: connecting these capabilities through integrated development models and collaborative partnerships to help therapies and diagnostics reach patients faster. Key insights from the discussion: ▪️ AI, proteomics and advanced analytics are helping researchers generate deeper biological insights and make better decisions earlier in development. ▪️ Companion diagnostics and biomarkers are increasingly being developed alongside therapies to help identify the right patients and improve clinical trial outcomes. ▪️ Connecting discovery, clinical development, diagnostics and manufacturing earlier can help reduce complexity, de-risk development programs and accelerate timelines. ▪️ Collaboration across the life sciences ecosystem remains essential to turning scientific breakthroughs into real-world patient impact. As Daniella Cramp shared, “A truly successful innovation is not defined only by what it can do scientifically. It is defined by whether it changes what is possible for a patient.” Together, science, data, diagnostics and manufacturing are creating new opportunities to accelerate innovation and help more patients benefit from the next generation of therapies. Thank you to the Maryland Tech Council, moderator Kaustabh Basu and TrilliumBiO’s Kellen Voss for a thoughtful discussion on the future of patient-focused innovation.